Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.
Journal: The Journal of urology
Published: June 10, 2026
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.
Journal: Prostate cancer and prostatic diseases
Published: June 11, 2025
Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF).
Journal: ASAIO journal (American Society for Artificial Internal Organs : 1992)
Published: April 29, 2025
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Journal: Future oncology (London, England)
Published: December 21, 2023
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 30, 2023
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
Journal: European urology
Published: February 14, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 18, 2022
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.
Journal: American journal of cancer research
Published: October 11, 2021
Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal: Cancer management and research
Published: September 11, 2021
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
Journal: The Journal of urology
Published: May 27, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 29, 2021
Last Updated: 09/26/2026